Projects

Bayh-Dole Act analogues

The Bayh-Dole Act (USA, 1980) governs the patenting and licensing of publicly funded research in the USA. It has a mixed record despite strong positive rhetoric. Similar Acts are now being developed in both India and South Africa. UAEM has analyzed the development of these new Acts. [Read More]

Canadian legislation

UAEM is supporting the efforts by the Canadian HIV/AIDS Legal Network to reform Canada's Access to Medicines Regime (CAMR), patent legislation intended to allow generic Canadian production of patented medications for export to poor countries, but underused due to excessive red tape. [Read More]

International agreements

UAEM is participating in the discussions of the WHO's Intergovernmental Working Group on Public Health, Innovation and Intellectual Property. [Read More]

Neglected disease research

We try to stimulate more research and development to meet the needs of the poor, including on new treatments, diagnostics, and vaccines for neglected tropical diseases. [Read More]

Patent pools

UAEM is working to convince university technology transfer offices to engage with the patent pools being developed by UNITAID (for HIV drugs) and GlaxoSmithKline (for neglected diseases). [Read More]

Student empowerment

We help students carry out successful campaigns on university campuses worldwide. We provide educational resources (including this web site) and individual advice, and we organize an annual conference. [Read More]

Technology transfer metrics

Developing new ways to measure the success of university technology transfer, emphasizing social impact. [Read More]

University of California campaign

UAEM is making a special effort to engage the University of California, and encourage them to practice global access licensing for all new medical technologies. [Read More]

University technology transfer

We aim to change the way universities commercialize drugs and other medical technologies, to protect low-cost access for the poor. This is UAEM's biggest and longest-running campaign, and is ongoing at universities around the world. [Read More]

USA legislation

Campaigns around excessive protection of 'biologic' drug patents (2009), and global access provisions for federally funded research (2006). [Read More]